Text and Data Mining valid from 2019-05-15
Received: 20 February 2018
Accepted: 2 May 2019
First Online: 15 May 2019
: C.C. and B.C. have filed a patent application on the use of A2AR agonists to treat and prevent osteoarthritis. B.C. holds patents numbers 5,932,558; 6,020,321; 6,555,545; 7,795,427; adenosine A1R and A2BR antagonists to treat fatty liver (pending); adenosine A2AR agonists to prevent prosthesis loosening (pending). B.C. is a consultant for AstraZeneca and Horizon Pharmaceuticals. BNC has stock in CanFite Biopharmaceuticals and Regenosine, Inc. C.C. has stock in Regenosine, Inc. A.U. does not have competing interests.